Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> TrialEric F. Morand, Shalabh Singhal, Ian M. Catlett et al.|Arthritis & Rheumatology|2022Cited by 246
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)Lauren Stevenson, Nisha Palackal, Sam Haidar et al.|Bioanalysis|2018Cited by 53